Group 3 Pulmonary Hypertension: From Bench to Bedside

Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.

  • Singh, N.
  • Dorfmüller, P.
  • Shlobin, O. A.
  • Ventetuolo, C. E.

Keywords

  • Humans
  • *Hypertension, Pulmonary/drug therapy/epidemiology
  • Lung
  • *Lung Diseases, Interstitial/complications/drug therapy
  • Vasodilator Agents
  • *Ventricular Dysfunction, Right/drug therapy
  • hypertension, pulmonary
  • hypoxia
  • lung diseases, interstitial
  • prevalence
  • ventricular dysfunction, right
Publication details
DOI: 10.1161/circresaha.121.319970
Journal: Circ Res
Pages: 1404-1422
Number: 9
Work Type: Review
Access number: 35482836
chevron-down